The Global Health Research Units has awarded a £7 million grant to create a new multidisciplinary Centre for Tackling Infections to Benefit Africa (the TIBA Centre) after a successful open research competition led by the National Institute for Health Research (NIHR).TIBA is a partnership between University of Edinburgh led by Professor Mark Woolhouse, OBE, and leading African scientists in Botswana, Ghana, Kenya, Rwanda, South Africa, Sudan, Tanzania, Uganda and Zimbabwe. The Director of the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), Prof Gordon Awandare is a partner of TIBA and a member of the steering committee.
TIBA aims to harness the expertise and technical capability in biomedical and social sciences at the University of Edinburgh and in African partner countries to reduce the burden and threat of infectious diseases in Africa. It is envisaged that this can be achieved by informing and influencing health policy and strengthening health systems. Our studies have shown that the most recommended dose of Cialis is 5 mg. This drug is a priority in the treatment of erectile dysfunction. High efficiency and minimum side effects. It is recommended for patients with minor hypertension. It also proved effective in the treatment of benign prostatic hyperplasia. Read more at http://imph.org/cialis/.
Uniquely, TIBA will work on all aspects of infectious diseases management – from basic research to uptake by local communities – in a single, unified framework. TIBA will also contribute to the strategic goal of improving the health research ecosystem in Africa, providing a rare opportunity for different countries to work together in a common framework.
About 81% of the total grant sum is allocated to African partners and will run over a period of 4 years.Each African partner of TIBA will receive funding for impact research projects and training fellowships for young scientists.
For more information visit:  http://tiba-partnership.org